Friday, April 5, 2013

BIO backs Fla. bill restricting biosimilar substitutions

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/epsoCduTtWCimLkCCidncVCicNgRWV

April 5, 2013
Reduce your company's energy expenses through the BIO Business Solutions program's newest initiative. BIO has aligned with APPI Energy, an energy consulting firm, to assist its member companies save on electrical and natural gas costs.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • BIO backs Fla. bill restricting biosimilar substitutions
    BIO praised a Florida Senate committee for passing a bill that would require pharmacists to notify physicians when a biosimilar drug was substituted for a brand-name biologic. S.B. 732 has a five-year sunset clause like the law signed in Virginia last month. "Biosimilars are not generics. Even slight changes to a biologic drug can change its properties entirely. Unlike conventional generic medicines, biosimilars are not the same as the drugs they seek to substitute," the BIO statement said. Drug Store News (4/4) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Enlivex's GVHD drug Apocell wins orphan status from FDA
    The FDA has granted orphan-drug designation to Enlivex Therapeutics' Apocell, an experimental drug for graft-versus-host disease. The designation will give the drug seven years of market exclusivity and "significant regulatory easements, which we believe will shorten marketing approval of the drug in the US, reducing costs," Enlivex CEO Alon Moran said. Globes (Israel) (4/3) LinkedInFacebookTwitterEmail this Story
  • FDA clears trial of Ampio's knee osteoarthritis drug
    Ampio Pharmaceuticals obtained FDA approval to initiate a clinical trial of Ampion, a non-steroidal anti-inflammatory biologic drug, in patients with knee osteoarthritis. Ampio is eligible to submit a biologics license application once the trial ends. BeckersASC.com (4/4) LinkedInFacebookTwitterEmail this Story
  • GSK's vasculitis drug enters late-stage trial
    GlaxoSmithKline initiated a late-stage trial to assess the safety and efficacy of Benlysta, or belimumab, in combination with azathioprine, in patients with antineutrophil cytoplasmic antibody-positive vasculitis. Benlysta has already been approved in the U.S. and Europe as an add-on treatment for systemic lupus erythematosus. Pharmaceutical Business Review Online (4/4) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
 
  • Supermarket's biotech labeling initiative spreads misperception
    Whole Foods Market's decision to label all biotech food in its stores would not only raise grocery prices, it would also spread misperceptions that biotech foods are not safe and nutritious to eat, Truth About Trade & Technology board member Ted Sheely writes in this commentary. Studies carried out by various groups and agencies including the American Medical Association and the FDA concluded that biotech foods are safe to eat, and there's no nutritional difference between biotech and non-biotech foods, Sheely writes. Western Farm Press (4/4) LinkedInFacebookTwitterEmail this Story
 
Two courses in four days at MIT Sloan Exec Ed
Learn from world-renowned faculty at MIT Executive Education and make the most of your visit with back-to-back two-day courses. Understand big data, revitalize your digital business model, solve complex business problems, drive strategic innovation.
View 25+ short courses.

  Industrial & Environmental 
  • Filing deadline for biodiesel mixture payments is moved to July 1
    The IRS set July 1 as the new filing deadline of payments for biodiesel mixtures and alternative fuels used or sold in 2012. The deadline was moved in line with the American Taxpayer Relief Act of 2012, which extended through 2013 the alternative fuels credit, the cellulosic biofuel producer credit, the biodiesel mixture credit, the alternative fuel mixtures credit and the refundable excise tax credit for biodiesel mixtures and alternative fuels. BiodieselMagazine.com (4/4) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • Win an Apple TV, $100 Visa gift card, Keurig coffee system ...
    ... and other valuable prizes at the BIO International Convention, April 22-25 in Chicago. Try your luck at the raffle at the BIO Partner Pavilion, Booth No. 3651, where you can win great prizes as well as learn how your company can save money through the BIO Business Solutions cost-savings program. Visit Booth #3651 to collect your raffle card, then follow the instructions to be eligible for the raffle drawing. And return from the Convention with ways to save your company money on products and services through the BIO Business Solutions program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
I believe in getting into hot water; it keeps you clean."
--G.K. Chesterton,
British writer


LinkedInFacebookTwitterEmail this Story

 
 
This SmartBrief was created for jmabs1@gmail.com
 
Subscriber Tools
     
Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information

No comments: